AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15947831
Drug: 0.9% physiological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% physiological saline solution
Trial: 12199971
Drug: Pressurized metered-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized metered-dose inhalers (MDIs)
Trial: 10424324
Drug: Loperamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4 mg at -24, -12 h and -1 h)
Trial: 10424324
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg q.i.d, first dose 3 days before study)
Trial: 8524984
Drug: ipsapirone (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipsapirone (0.3 mg per kg body weight)
Trial: 2273527
Drug: Nicotine (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine (1.0 mg FTC‐estimated nicotine delivery)
Trial: 7006783
Drug: Different types
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different types of therapy for five types of glomerulonephritis (specific therapies not detailed in the abstract)
Trial: 31879033
Drug: SYDNEY device
RxNorm normalized name: Sydney golden wattle pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SYDNEY device (1 × 300 mg injection)
Trial: 31879033
Drug: Currently approved
RxNorm normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Currently approved autoinjector (2 × 150 mg injections)
Trial: 20934265
Drug: Combined modality
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined modality treatment (CMT) using radiotherapy (RT), infusional 5‐fluorouracil, and mitomycin C
Trial: 20934265
Drug: Iridium-192 implant
RxNorm normalized name: iridium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iridium-192 implant boost (25 Gy)
Trial: 15188832
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg danazol three times daily for 6 months
Trial: 15188832
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg leuprorelin acetate depot every 28 days for 6 months
Trial: 8110557
Drug: dobutamine 10
RxNorm normalized name: DOBUTamine 1000 MG in 250 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dobutamine 10 micrograms kg‐1 min‐1 before discontinuation of CPB
Trial: 8110557
Drug: enoximone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoximone 0.5 mg kg‐1 followed by an infusion of 10 micrograms kg‐1 min‐1 before discontinuation of CPB
Trial: 28320794
Drug: Community health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community health volunteers (CHVs) offering free rapid diagnostic tests (RDTs) and vouchers for WHO-qualified artemisinin combination therapy (ACT) at a reduced price.
Trial: 23551657
Drug: Celecoxib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg twice a day for 14 days)
Trial: 23551657
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard medical treatment for ICH)
Trial: 21450118
Drug: 4 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 × 240 ml black tea providing 168 mg of caffeine
Trial: 21450118
Drug: 6 ×
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 × 240 ml black tea providing 252 mg of caffeine
Trial: 17473069
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose L‐T4 (subclinical hypothyroid arm)
Trial: 17473069
Drug: Usual dose
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual dose L‐T4 (euthyroid arm)
Trial: 9677446
Drug: Pre-operative radiation
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative radiation therapy followed by cystectomy
Trial: 7932278
Drug: Alprazolam treatment
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam treatment over 8 weeks
Trial: 29024081
Drug: Rosa canina
RxNorm normalized name: ROSA CANINA SEED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosa canina fruit capsules (500 mg, twice daily for 20 days)
Trial: 27138026
Drug: Reference tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference tablets (coadministered commercially available amlodipine and rosuvastatin)
Trial: 15844319
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) injection (10 microg/d for 10 days in one month, for a total of 6 months)
Trial: 15844319
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) injection
Trial: 15844319
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no PGE1, same other therapy)
Trial: 10403876
Drug: Cerebral palsy
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral palsy not taking anticonvulsant medication
Trial: 10403876
Drug: Cerebral palsy
RxNorm normalized name: Sus scrofa cerebral cortex preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebral palsy taking anticonvulsant medication
Trial: 2160343
Drug: Low sodium,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low sodium, cholesterol lowering diet (less than 60 mmol/day sodium, 30% energy from fat, high P/S ratio, 30-50 g/day fibre)
Trial: 2160343
Drug: Sodium supplement
RxNorm normalized name: Sodium supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium supplement (100 mmol/day NaCl)
Trial: 29986150
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of MCT alone (30 g·day‐1)
Trial: 29021908
Drug: Fustra20Neck&Back exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fustra20Neck&Back exercise program, individually guided neuromuscular exercise twice weekly for 10 weeks
Trial: 25546379
Drug: Low-dose active
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose active (LDA) group: 500 mg of flaxseed hull extract containing 100 mg of secoisolariciresinol diglucoside (SDG), n=26
Trial: 25546379
Drug: High-dose active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose active (HDA) group: 1000 mg of flaxseed hull extract containing 200 mg of secoisolariciresinol diglucoside (SDG), n=26
Trial: 25546379
Drug: Placebo (P)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P) group: matching maltodextrin capsules, n=28
Trial: 21301382
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (1.25 mg/0.05 mL) every 4 weeks
Trial: 2635350
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (ABM) 1.5 mg.kg-1
Trial: 2635350
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (ABM) 2.25 mg.kg-1
Trial: 2635350
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (ABM) 0.75 mg.kg-1
Trial: 370525
Drug: Bromocriptine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (5 mg per day) during the luteal phase
Trial: 30866856
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA‐α) injection (0.45 μg/kg once weekly subcutaneously)
Trial: 30866856
Drug: EPO (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPO (50 IU/kg thrice weekly subcutaneously)
Trial: 28100192
Drug: Other basal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other basal insulin regimens
Trial: 27190323
Drug: Emapticap (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emapticap (0.5 mg/kg)
Trial: 17966757
Drug: Amiodarone 200
RxNorm normalized name: amiodarone 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 200 mg tablet with food
Trial: 17966757
Drug: Amiodarone 200
RxNorm normalized name: amiodarone 200 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 200 mg tablet without food
Trial: 14588350
Drug: Nonoperative management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative management (spinal extensor muscle-strengthening exercise, medications, and restricted duty)
Trial: 7512336
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment for AMD
Trial: 7512336
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment for ocular histoplasmosis
Trial: 7512336
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment for idiopathic choroidal neovascularization
Trial: 7512336
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment for normotensive patients with AMD
Trial: 7512336
Drug: Krypton laser
RxNorm normalized name: krypton (81mKr) gas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Krypton laser treatment for hypertensive patients with AMD
Trial: 2974719
Drug: 5% benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% benzoyl peroxide gel (Benzac W5)
Trial: 2974719
Drug: 1% clindamycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% clindamycin phosphate solution (Cleocin T)
Trial: 26168743
Drug: Methocarbamol (Ortoton),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methocarbamol (Ortoton), orally administered for up to 8 days
Trial: 18355507
Drug: Intravenous cariporide
RxNorm normalized name: Cariporide
DrugBank: Cariporide (DB06468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cariporide (180 mg in a 1-hour preoperative loading dose, then 40 mg per hour over 24 hours and 20 mg per hour over the subsequent 24 hours)
Trial: 18355507
Drug: Intravenous cariporide
RxNorm normalized name: Cariporide
DrugBank: Cariporide (DB06468)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cariporide
Trial: 12609781
Drug: Lymecycline 300
RxNorm normalized name: lymecycline 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline 300 mg od
Trial: 12609781
Drug: Lymecycline 150
RxNorm normalized name: lymecycline 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymecycline 150 mg bid
Trial: 10396008
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (pharmacotherapy + cognitive‐behavioral psychotherapy)
Trial: 7555472
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (insulin + OHAs)
Trial: 7555472
Drug: Insulin group
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin group (insulin alone)
Trial: 2100046
Drug: Apomorphine (different
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apomorphine (different doses, subcutaneously)
Trial: 395630
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (1 g intravenously six times daily for a maximum of 3 days, followed by 1.5 g orally four times daily for a maximum of 4 days)
Trial: 25964070
Drug: Rosiglitazone 4
RxNorm normalized name: rosiglitazone 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone 4 mg and 8 mg daily
Trial: 19166691
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day (monotherapy)
Trial: 19166691
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg/day (add-on to statin therapy)
Trial: 29634656
Drug: Prolastin C,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolastin C, plasma-derived AAT, at 60 mg/kg infused intravenously within 12 hours of reperfusion
Trial: 27513506
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (2.24 g daily) in skim milk (350 ml twice daily) for 3 weeks
Trial: 16554145
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg the day before and 1200 mg on race day)
Trial: 12610048
Drug: Participants on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants on hypoglycemic agents
Trial: 10771455
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 mg + Cimetidine 800 mg
Trial: 10771455
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 mg + Maalox
Trial: 10771455
Drug: Ziprasidone 40
RxNorm normalized name: ziprasidone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone 40 mg alone
Trial: 9238880
Drug: Oral‐B 35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B 35 manual toothbrush (Control)
Trial: 1450081
Drug: Standard protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protocol treatment
Trial: 7442597
Drug: Etofibrate (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etofibrate (500 mg, sustained release, 1 capsule per day)
Trial: 26987409
Drug: Glucose solutions
RxNorm normalized name: glucose Injectable Solution
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose solutions (4%, 16%, 48%)
Trial: 22198979
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy for 3 nights starting the first night after stroke onset, with additional nights based on apnea-hypopnea index results.
Trial: 22198979
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy (excellent use)
Trial: 22198979
Drug: CPAP therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP therapy (some use)
Trial: 10580624
Drug: Nasal mupirocin
RxNorm normalized name: mupirocin Nasal Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal mupirocin calcium ointment 2% administered twice a day for 5 days followed by twice monthly applications.
Trial: 10580624
Drug: Nasal mupirocin
RxNorm normalized name: mupirocin Nasal Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal mupirocin calcium ointment 2%
Trial: 6223584
Drug: SPG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPG (20 mg twice a week or 40 mg once a week) with MF protocol (mitomycin C + 5-fluorouracil)
Trial: 6223584
Drug: SPG (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPG (20 mg twice a week or 40 mg once a week) with F protocol (tegafur)
Trial: 30826311
Drug: Tolnaftate solution
RxNorm normalized name: Tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tolnaftate solution
Trial: 27641510
Drug: Rabeprazole (PPI),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole (PPI), 20 mg once daily
Trial: 27641510
Drug: Famotidine (H2RA),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine (H2RA), 40 mg once daily
Trial: 19761718
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg film‐coated tablet of avosentan
Trial: 19761718
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg film‐coated tablet of avosentan
Trial: 19761718
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg avosentan in 20 ml solution for infusion
Trial: 15319761
Drug: Chiropractic adjustments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chiropractic adjustments with placebo medicine
Trial: 15319761
Drug: Placebo medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medicine with sham adjustments
Trial: 11003931
Drug: Hemodynamic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemodynamic treatment guided by gastric intramucosal pH monitoring
Trial: 1389938
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of the 5 mu diameter particle
Trial: 1389938
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of the 2 mu diameter particle
Trial: 6208841
Drug: Flecainide (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (375 mg)
Trial: 6208841
Drug: Quinidine (660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (660 mg)
Trial: 30169436
Drug: Methylphenidate (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (optimal dose of 40.5 mg, 1.00 mg/kg/day)
Trial: 20400412
Drug: Memantine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (40 mg/day or maximum tolerated dose)
Trial: 17299464
Drug: Purple sweet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purple sweet potato (PSP) beverage (200.3 mg anthocyanins per 125 ml per bottle), consumed two bottles per day for 8 weeks
Trial: 17299464
Drug: Placebo beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo beverage (1.7 mg anthocyanins per 125 ml per bottle), consumed two bottles per day for 8 weeks
Trial: 15968232
Drug: Metoclopramide (started
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (started at 5 mg daily, titrated to a maximum of 40 mg daily)
Trial: 10566623
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of radioiodine WBS and serum Tg after recombinant human TSH stimulation
Trial: 1905602
Drug: Bayesian pharmacokinetic
RxNorm normalized name: Babesia microti preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bayesian pharmacokinetic dosing program
Trial: 1905602
Drug: Dosing based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing based on physician choice (Control)
Trial: 6333518
Drug: Prophylactic antibacterial
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic antibacterial preparation
Trial: 6333518
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic antibacterial preparation (Control)
Trial: 3578852
Drug: 10 ml
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.25% bupivacaine
Trial: 24627416
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (DAPT) adherence in E‐ZES group
Trial: 11605086
Drug: Gaboxadol 20
RxNorm normalized name: Gaboxadol
DrugBank: Gaboxadol (DB06554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaboxadol 20 mg
Trial: 11303489
Drug: 4.4 mg
RxNorm normalized name: pectin 4.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 mg beta-carotene from DGLV (n=37, after 18 dropouts)
Trial: 11303489
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg beta-carotene from sweet pumpkin (n=36, 18 dropouts)
Trial: 11303489
Drug: DGLV (4.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DGLV (4.4 mg beta-carotene)
Trial: 8257551
Drug: Buprenorphine (0.6‐1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (0.6‐1.2 mg per day, sublingually)
Trial: 8257551
Drug: Clonidine (0.3‐0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.3‐0.9 mg per day, oral)
Trial: 3084315
Drug: Glibenclamide (7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide (7 mg before breakfast and 3.5 mg before supper)
Trial: 11688590
Drug: Functional physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional physical therapy
Trial: 11688590
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group physical therapy (normalization of quality of movement)
Trial: 27401338
Drug: Glutamine-enriched nutritional
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-enriched nutritional therapy (peptamen + glutamine)
Trial: 19785609
Drug: Terbinafine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine with iontophoretic patch (100 microA cm(‐2))
Trial: 15607126
Drug: Oral NAC
RxNorm normalized name: NAC
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral NAC 600 mg b.i.d. for 2 months
Trial: 12404705
Drug: Ginkgo-Ginseng combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo-Ginseng combination (320 mg)
Trial: 12404705
Drug: Ginkgo-Ginseng combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo-Ginseng combination (640 mg)
Trial: 12404705
Drug: Ginkgo-Ginseng combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo-Ginseng combination (960 mg)
Trial: 10102436
Drug: Albendazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole (15 mg/kg/d for 1 week)